NCT07779005Recruiting
The Shengjing Lung Cancer Cohort (SJ-LCC) Study on Risk Factors for Disease Development and Progression
The Shengjing Lung Cancer Cohort (SJ-LCC) Study
Source: ClinicalTrials.gov · Last updated 21 Aug 2026
Brief summary (registry, in English)
Modifiable risk factors, including smoking, alcohol consumption, and diet, play critical roles in cancer progression and patient prognosis. In patients diagnosed with lung cancer, these risk factors not only directly modulate host metabolism and immune regulation, but also exert indirect effects by altering the internal milieu, such as the gut microbiota-potentially exerting a profound impact on long-term clinical trajectories. Leveraging a well-characterized, longitudinally followed cohort of confirmed lung cancer patients, this study systematically assesses habitual dietary intake, emotional well-being, lifestyle behaviors, and related variables using validated instruments, including the Food Frequency Questionnaire (FFQ). Furthermore, the study integrates multidimensional biomarker profiling across tumor tissue, blood, urine, and fecal samples. By linking exposure profiles, multi-omics data, and long-term clinical follow-up records, this project aims to: 1. Evaluate Prognostic Associations: Investigate the relationships between exposure profiles (e.g., dietary patterns) and long-term clinical outcomes in lung cancer patients, including progression-free survival (PFS), overall survival (OS), and recurrence risk. 2. Elucidate Biological Mechanisms: Unravel the underlying mechanisms by which the "exposure profile-multi-omics" axis mediates lung cancer progression, and identify candidate biomarkers with predictive value for clinical prognosis. Ultimately, this study aims to establish evidence-based healthy lifestyle recommendations for patients and provide healthcare professionals with translational insights to inform precision nutrition and targeted intervention strategies across the continuum of lung cancer care.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1500 (estimated)
- First submitted
- 19 Aug 2026
- Start date
- 1 Feb 2019
- Primary completion date
- 30 Dec 2024
- Lead sponsor
- Shengjing Hospital
- Diseases
- Lung cancer
- NCT number
- NCT07779005
What you commit to
- Study type: Observational
- Planned participants: 1500
- From 1 Feb 2019 to the primary completion date, 30 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with non-primary lung cancer, non-newly diagnosed lung cancer, or those unable to provide definitive pathological confirmation;
- Individuals with severe depression, pregnant women, or those diagnosed with severe cardiovascular/cerebrovascular diseases or severe metabolic dysfunctions affecting the liver, kidneys, or other major organs;
Age
- Individuals aged outside the range of 18-75 years, or those in poor general physical condition who are unable to cooperate with the questionnaire survey;
Other
- Individuals unwilling to participate in the study.
Who the study is looking for
- Patients aged between 18 and 75 years;
- Patients with newly, pathologically confirmed lung cancer;
- Patients diagnosed within the preceding 6 months (time since confirmed diagnosis \< 6 months).
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shengjing Hospital affiliated to China Medical University Coordinator of this site? Confirm its status | Shenyang | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.